ClinicalTrials.gg
TerminatedNCT05172115CANARYUpdated Dec 29, 2021

Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE

A Phase 3 interventional study of Conventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA) and Enoxaparin in Pulmonary Embolism, Pulmonary Thromboembolisms and Embolism, Pulmonary, sponsored by Rajaie Cardiovascular Medical and Research Center. Terminated at 1 site in Iran, Islamic Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-29.

Sponsored by Rajaie Cardiovascular Medical and Research Center · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Due to the COVID-19 pandemic

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Dec 2018, registered Dec 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In an open-label parallel groups blinded-endpoint randomized clinical trial, the investigators aim to assess the safety and efficacy of conventional catheter-directed thrombolysis (CDT) vs anticoagulation monotherapy on outcomes of patients with acute intermediate-high risk pulmonary embolism. The investigators hypothesize that CDT will have a superior efficacy and safety compared with anticoagulation-only therapy regarding the proportion of patients with a right ventricle to left ventricle (RV/LV) ratio > 0.9 at a 3-month follow-up by an imaging core laboratory, major bleeding, severe thrombocytopenia, or vascular access complication.

Read the detailed description

Treatment of intermediate risk PE is still debated. Despite the promising results of small studies on the efficacy and safety of systemic thrombolytic therapy, larger trials failed to show a net clinical benefit. Pulmonary EmbolIsmTHrOmbolysis (PEITHO) trial which compared the full-dose systemic thrombolysis (i.e., tenecteplase) versus anticoagulation therapy in patients with intermediate-risk PE showed significant lower incidence of mortality or hemodynamic collapse in the first 7 days after randomization in patients who received tenecteplase (2.6% vs 5.6% in placebo group, [odds ratio, 0.44; 95% confidence interval, 0.23 to 0.87; P value, 0.02]). However the mortality benefit was neutralized by the increased risk of major bleeding in thrombolytic arm (11.5% vs 2.4% in the tenecteplase and placebo group, respectively. Importantly, during the long-term follow up (median of 37.8 months) of PEITHO participants, the thrombolytic therapy failed to improve the RV right ventricular function, residual dyspnea ( 36% in thrombolysis group vs 30.1% in the placebo group), or mortality rates (20.3% in thrombolysis group vs 18 % in the placebo group ). CTEPH occurred in ( 2.1% in thrombolysis group vs 3.2% in the placebo group. The lack of benefit of full-dose thrombolytic in PEITHO, might have several explanations. Intermediate risk PE compose of heterogenous group of patients with different prognosis in whom one fits all approach would not be applicable. This heterogeneity in prognosis were underlined in the latest guideline of the European Society of Cardiology (ESC) which classified the intermediate-risk PE category into two groups of intermediate-low and intermediate-high risk patients according to the right ventricle function and cardiac biomarker levels. Second, lower-dose thrombolytic regimen might result in the same benefit with lower bleeding events. CDT, by delivering drug locally, claims to increase the efficacy of thrombolytic agents and consequently decrease the required dose which might translate to lower bleeding events.

In an open-label parallel groups blinded-endpoint randomized clinical trial, we aim to evaluate the safety and efficacy of standard catheter-directed thrombolysis (CDT) vs anticoagulation-only therapy in patients with acute intermediate-high risk pulmonary embolism. The hypothesis is that CDT will have a superior efficacy and safety regarding the proportion of patients with a RV/LV ratio > 0.9 at a 3-month follow-up assessed by an imaging core laboratory with the lower complications of major bleeding, severe thrombocytopenia, and vascular access complication.

02

Conditions studied

  • Pulmonary Embolism
  • Pulmonary Thromboembolisms
  • Embolism, Pulmonary
  • Right Ventricular Dysfunction

Keywords

  • Intermediate-high risk pulmonary embolism
  • Catheter-directed thrombolysis
  • Anticoagulation
03

In context

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

This study's enrollment of 94 is below the median of 174 across 430 interventional studies indexed under Pulmonary Embolism.

Browse Pulmonary Embolism studies →

Lead sponsor

Rajaie Cardiovascular Medical and Research Center is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 years
  2. Confirmed acute pulmonary emboli by computed tomography pulmonary angiography (CTPA)
  3. Symptom onset ≤14 day
  4. Elevated N-terminal-proB-type natriuretic peptide and cardiac troponin
  5. Right ventricle/left ventricle ratio >0.9 in transthoracic echocardiography
  6. Less than 48 hours of anticoagulation therapy
  7. Willingness for participation in the study with signed and dated form

Exclusion criteria

Exclusion Criteria:

  1. Pulmonary emboli detected by modalities other than CTPA
  2. Segmental PE
  3. High risk (massive)
  4. Severe renal dysfunction( [CrCl] below 30 mL/min)
  5. Terminal illness Surgery within 2 weeks
  6. count \<50.000 /µL
  7. Pre and post catheter directed thrombolysis echocardiography exam not possible
  8. to thrombolytic therapy
  9. Concomitant right heart thrombi
  10. Allergic reaction to study medications
  11. Lack or withdrawal of
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Conventional catheter-directed thrombolysis (CDT)

    Conventional catheter-directed thrombolysis (CDT) will be the interventional arm. CDT will be administered using fixed-dose of 24 mg tissue plasminogen activator infusion over 24 hours (0.5 mg/h per catheter if bilateral or 1 mg/h per unilateral catheter) with 500 unit per hour of infusion of unfractionated heparin during the thrombolytic therapy. The therapeutic dose of heparin will immediately be substituted the CDT after termination, and twice-daily subcutaneous enoxaparin (1mg/kg) for the first 48 hours after the thrombolytic therapy will be administered. Direct oral anticoagulation will be in ones with no clinical deterioration.

    Procedure: Conventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA)

  • Active comparator
    Anticoagulation-only therapy

    The anticoagulation-only therapy will be the assigned treatment in the control arm. Control patients will receive subcutaneous enoxaparin (twice-daily, 1mg/kg) in the first 48hours of enrollment. Direct oral anticoagulation will be in ones with no clinical deterioration.

    Drug: Enoxaparin

Interventions

  • ProcedureConventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA)

    Conventional catheter-directed thrombolysis with fixed-dose of 24 mg tissue plasminogen activator infusion over 24 hours

    Also known as: Cragg-McNamara™ valved infusion catheters

  • Subcutaneous enoxaparin twice-daily (1mg/kg)

    Also known as: low molecular weight heparin (LMWH)

06

What researchers measure

Primary outcomes

  1. The proportion of patients with a RV/LV ratio >0.9

    Proportion of patients with a RV/LV ratio \>0.9 at a assessed by an imaging core laboratory 3-month follow-up

    Time frame: At 3 months from randomization

Secondary outcomes

  1. The proportion of patients with an RV/LV ratio >0.9

    A composite of the proportion of patients with a RV/LV ratio \>0.9 at a assessed by an imaging core laboratory 72 hours follow-up

    Time frame: At 72 hours from randomization

  2. The proportion of patients with Unrecovered RV

    The PEITHO definition for RV recovery was employed, as follows: 1) RV size (at the mid-cavity level In apical 4-chamber view) \<35 mm, 2) pulmonary artery pressure \<35 mm Hg, 3) an RV/LV ratio \<0.9, and 4) the normalization of RV free wall motion. The fulfillment of all the criteria, some criteria, and none of the criteria was defined as complete, partial, and no recovery, respectively.

    Time frame: At 3 months from randomization

  3. All-cause mortality

    Survival status of the patient (being alive or dead) at the end of 3 months follow up

    Time frame: Within 3-month Study period

  4. Major bleeding

    According to the Bleeding Academic Research Consortium (BARC 3 or 5 bleeding)

    Time frame: Within 3-month Study period

  5. Severe thrombocytopenia

    Platelet count \<20.000/µL

    Time frame: Within 3-month Study period

  6. Vascular access complication

    Major vascular access complication

    Time frame: Within 3-month Study period

Other outcomes

  1. A composite of all-cause death or the primary outcome

    Composite patients who died or patients with a RV/LV ratio \>0.9 at a assessed by an imaging core laboratory 3-month follow-up

    Time frame: Within 3-month Study period

  2. PE-related mortality.

    Autopsy-confirmed PE with no more likely cause of death or objectively confirmed PE before death in the absence of another more likely cause of death

    Time frame: Within 3-month Study period

  3. Hospital length of stay

    The total days of the initial hospitalization

    Time frame: Within 3-month Study period

  4. Six-minute walk test (6MWt) at three-month follow up

    The functional capacity of the patient

    Time frame: Within 3-month Study period

07

Study locations

1 site
  • Rajaie Cardiovascular Medical and Research Center
    Tehran, 1995614331, Iran, Islamic Republic of
08

References and documents

Publications

  • Sadeghipour P, Jenab Y, Moosavi J, Hosseini K, Mohebbi B, Hosseinsabet A, Chatterjee S, Pouraliakbar H, Shirani S, Shishehbor MH, Alizadehasl A, Farrashi M, Rezvani MA, Rafiee F, Jalali A, Rashedi S, Shafe O, Giri J, Monreal M, Jimenez D, Lang I, Maleki M, Goldhaber SZ, Krumholz HM, Piazza G, Bikdeli B. Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High-risk Pulmonary Embolism: The CANARY Randomized Clinical Trial. JAMA Cardiol. 2022 Dec 1;7(12):1189-1197. doi: 10.1001/jamacardio.2022.3591. PubMed 36260302 ↗

Individual participant data

Plan to share: No — Data will become available to interested investigators upon submitting a reasonable research request, approved by the Steering Committee of the trial.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Feb 2020, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2021
First posted
Dec 29, 2021
StartActual
Dec 22, 2018
Primary completionActual
Feb 2, 2020
CompletionActual
May 2, 2020
Last update
Dec 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05172115
Lead sponsor
Rajaie Cardiovascular Medical and Research Center
Responsible party
Parham Sadeghipour (Associate Professor, Rajaie Cardiovascular Medical and Research Center) — Principal investigator
First posted
Dec 29, 2021
Start date
Dec 22, 2018
Primary completion
Feb 2, 2020
Completion
May 2, 2020
Last update
Dec 29, 2021

Study contacts

Parham Sadeghipour, M.D
principal investigator · Rajaie Cardiovascular Medical and Research Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion